Rev Esp Enferm Dig. 2022 Nov 10. doi: 10.17235/reed.2022.9228/2022. Online ahead of print.
ABSTRACT
BACKGROUND AND AIMS: Vonoprazan, a novel potassium-competitive acid blocking agent, has better clinical outcomes in the treatment of acid-related diseases. However, some adverse events have been associated with Vonoprazan for the treatment of acid-associated diseases. Therefore, this systematic review and meta-analysis aimed to explore the safety and tolerability of Vonoprazan for acid-associated diseases.
METHODS: Electronic databases were retrieved to determine random control trials (RCTs) of Vonoprazan for acid-associated diseases with any adverse effects and discontinuation.
RESULTS: This systematic review and meta-analysis conforming to the selection criteria included 18 RCTs with a total of 7,932 participants. Compared with proton pump inhibitors, oral Vonoprazan treatment showed no significant increase in the incidence of adverse effects (95% CI = 0.987-1.095, p = 0.141). Diarrhoea or loose stools analysis showed that there was a statistically significant difference between Vonoprazan and PPIs treatment (95% CI = 0.661-0.966, p = 0.021). While there was no significant difference in constipation, rash or eruption, nausea or vomiting, bloating or abdominal pain, dysgeusia, nasopharyngitis, neurological disorders, upper respiratory tract infection and abnormal investigations between Vonoprazan and PPIs treatment.
CONCLUSION: Vonoprazan, which has better tolerability and safety, may significantly decrease diarrhoea and loose stools in acid-related patients compared with PPIs. Our meta-analysis led to safer strategies for treating acid-related diseases. More high-quality studies with larger sample sizes are needed to further identify its efficacy and safety.
PMID:36353962 | DOI:10.17235/reed.2022.9228/2022
